预防晚期前列腺癌的骨骼并发症。
Preventing bone complications in advanced prostate cancer.
机构信息
Division of Urology, Department of Surgery, McGill University, Montreal, QC.
出版信息
Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S65-71. doi: 10.3747/co.v17i0.722.
Abstract
The diagnosis and treatment of prostate cancer have steadily been improving since the late 1980s. However, clinicians still confront a large group of men developing disease metastatic to bone. Adequate control of bone complications plays a fundamental role in achieving control of symptoms and quality of life in this group. Androgen deprivation therapy, the standard treatment for advanced prostate cancer, increases the risk of various complications, including bone disease. This review addresses the prevention of bone complications related not only to prostate cancer metastases but also to impaired bone integrity caused by androgen deprivation therapy.
摘要
自 20 世纪 80 年代末以来，前列腺癌的诊断和治疗一直在稳步改善。然而，临床医生仍然面临着一大群发生骨转移疾病的男性。充分控制骨并发症对于控制这组患者的症状和生活质量起着至关重要的作用。雄激素剥夺疗法是晚期前列腺癌的标准治疗方法，会增加各种并发症的风险，包括骨疾病。本综述不仅涉及与前列腺癌转移相关的骨并发症的预防，还涉及雄激素剥夺治疗引起的骨完整性受损的预防。
相似文献
1
Preventing bone complications in advanced prostate cancer.预防晚期前列腺癌的骨骼并发症。
Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S65-71. doi: 10.3747/co.v17i0.722.
2
Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy.前列腺癌患者骨丢失和骨转移的管理：聚焦双膦酸盐治疗。
Rev Urol. 2008 Spring;10(2):99-110.
3
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.转移性去势敏感性前列腺癌中依泽替米贝联合雄激素剥夺治疗的疗效：ARCHES 事后分析。
J Urol. 2021 May;205(5):1361-1371. doi: 10.1097/JU.0000000000001568. Epub 2020 Dec 28.
4
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.晚期前列腺癌治疗中早期与延迟雄激素抑制疗法的比较
Cochrane Database Syst Rev. 2002(1):CD003506. doi: 10.1002/14651858.CD003506.
5
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.前列腺癌合并少量骨转移患者的减瘤性根治性前列腺切除术：一项可行性及病例对照研究的结果
J Urol. 2015 Mar;193(3):832-8. doi: 10.1016/j.juro.2014.09.089. Epub 2014 Sep 22.
6
Bone health in men receiving androgen deprivation therapy for prostate cancer.接受前列腺癌雄激素剥夺治疗的男性的骨骼健康
J Urol. 2007 Jan;177(1):17-24. doi: 10.1016/j.juro.2006.08.089.
7
Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer.雄激素剥夺疗法对转移性前列腺癌男性患者破骨细胞活性升高的作用。
Clin Cancer Res. 2004 Apr 15;10(8):2705-8. doi: 10.1158/1078-0432.ccr-03-0735.
8
Background to and management of treatment-related bone loss in prostate cancer.前列腺癌治疗相关骨质流失的背景与管理
Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002.
9
Practical guide to bone health in the spectrum of advanced prostate cancer.晚期前列腺癌患者骨骼健康实用指南
Can J Urol. 2014 Apr;21(2 Supp 1):84-92.
10
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.前列腺癌的骨骼健康与骨靶向治疗：循证护理计划——安大略癌症护理临床实践指南
Clin Oncol (R Coll Radiol). 2017 Jun;29(6):348-355. doi: 10.1016/j.clon.2017.01.007. Epub 2017 Feb 4.
引用本文的文献
1
Mechanical Loading of Osteocytes via Oscillatory Fluid Flow Regulates Early-Stage PC-3 Prostate Cancer Metastasis to Bone.通过振荡液流对骨细胞进行机械加载可调节PC-3前列腺癌早期骨转移。
Adv Biol (Weinh). 2025 Apr;9(4):e2400824. doi: 10.1002/adbi.202400824. Epub 2025 Feb 19.
2
Compressed Prostate Cancer Cells Decrease Osteoclast Activity While Enhancing Osteoblast Activity In Vitro.体外压缩前列腺癌细胞可减少破骨细胞活性，同时增强成骨细胞活性。
Int J Mol Sci. 2023 Jan 1;24(1):759. doi: 10.3390/ijms24010759.
3
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.镭-223 治疗转移性去势抵抗性前列腺癌男性患者的临床病理因素对预后和生存结局的影响。
Cancer Med. 2021 Sep;10(17):5775-5782. doi: 10.1002/cam4.4125. Epub 2021 Jul 13.
4
Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.加拿大魁北克省前列腺癌患者骨转移的疾病负担：一项基于人群的分析。
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):307-14. doi: 10.5489/cuaj.2707.
本文引用的文献
1
Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).使用特异性内皮素A受体拮抗剂昔多芬（ZD4054）治疗后无痛或症状轻微的转移性激素抵抗性前列腺癌患者的健康相关生活质量
J Cancer Res Clin Oncol. 2011 Jan;137(1):99-113. doi: 10.1007/s00432-010-0864-1. Epub 2010 Apr 14.
2
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.接受雄激素剥夺治疗的前列腺癌患者的骨骼健康：当前及未来管理方案综述
Can Urol Assoc J. 2010 Apr;4(2):129-35. doi: 10.5489/cuaj.811.
3
Diagnosis of bone metastases in urological malignancies--an update.泌尿系统恶性肿瘤骨转移的诊断——更新。
Urology. 2010 Oct;76(4):782-90. doi: 10.1016/j.urology.2009.12.050. Epub 2010 Mar 25.
4
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.西仑吉肽（EMD121974，NSC707544）治疗无症状转移性去势抵抗性前列腺癌患者的随机 II 期临床试验：前列腺癌临床研究联盟的研究。
Invest New Drugs. 2011 Dec;29(6):1432-40. doi: 10.1007/s10637-010-9420-8. Epub 2010 Mar 25.
5
Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.管理乳腺癌或前列腺癌患者癌症治疗相关的骨丢失和骨质疏松症。
Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S20-30; quiz S31-3. doi: 10.2146/ajhp100078.
6
Pathogenesis of osteoblastic bone metastases from prostate cancer.前列腺癌成骨性骨转移的发病机制。
Cancer. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896.
7
Bone health and prostate cancer.骨骼健康与前列腺癌。
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. doi: 10.1038/pcan.2009.50. Epub 2009 Nov 10.
8
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.口服氯膦酸钠辅助治疗局部晚期和转移性前列腺癌：MRC PR04和PR05随机对照试验的长期总生存结果
Lancet Oncol. 2009 Sep;10(9):872-6. doi: 10.1016/S1470-2045(09)70201-3. Epub 2009 Aug 10.
9
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.地诺单抗用于接受雄激素剥夺治疗的前列腺癌男性患者。
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
10
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.地诺单抗治疗伴有骨转移的前列腺癌及静脉注射双膦酸盐治疗后尿N-端肽水平升高：一项随机II期试验的结果
J Urol. 2009 Aug;182(2):509-15; discussion 515-6. doi: 10.1016/j.juro.2009.04.023. Epub 2009 Jun 13.
Zotero 插件